» Articles » PMID: 36289813

The Tumour Suppressor Fhit Protein Activates C-Raf Ubiquitination and Degradation in Human Melanoma Cells by Interacting with Hsp90

Overview
Journal Biomedicines
Date 2022 Oct 27
PMID 36289813
Authors
Affiliations
Soon will be listed here.
Abstract

Fhit protein expression is reduced in the majority of human tumors; moreover, its restoration both triggers apoptosis of cancer cells and suppresses tumor formation in a large number of preclinical models of cancers. In the following study, we observed that Fhit expression is significantly reduced in human melanoma cells, and their in vivo growth is blocked by a recombinant adenovirus carrying the gene. Importantly, we found here that Fhit physically interacts with Hsp90. Since Hsp90 is a chaperone with a crucial function in the conformational maturation and stabilization of C-Raf, we also investigated whether Fhit could interfere with the Hsp90/C-Raf protein complex in melanoma. Interestingly, the administration of the Hsp90 inhibitor 17-AAG, in combination with Fhit protein overexpression in melanoma cells, reacts synergistically to increase C-Raf ubiquitination and degradation. These data reveal Hsp90 as a novel interactor of Fhit and suggest that activity restoration could represent a helpful strategy for suppressing the oncogenic C-Raf pathway in the therapy of human melanoma.

Citing Articles

Advances in the structures, mechanisms and targeting of molecular chaperones.

Gu J, He Y, He C, Zhang Q, Huang Q, Bai S Signal Transduct Target Ther. 2025; 10(1):84.

PMID: 40069202 PMC: 11897415. DOI: 10.1038/s41392-025-02166-2.


Inhibition of GSK3β is synthetic lethal with FHIT loss in lung cancer by blocking homologous recombination repair.

Tao S, Pu Y, Yang E, Ren G, Shi C, Chen L Exp Mol Med. 2025; 57(1):167-183.

PMID: 39762409 PMC: 11799392. DOI: 10.1038/s12276-024-01374-0.


Alarmins in cutaneous malignant melanoma: An updated overview of emerging evidence on their pathogenetic, diagnostic, prognostic, and therapeutic role.

Papa V, Li Pomi F, Borgia F, Vaccaro M, Pioggia G, Gangemi S J Dermatol. 2024; 51(7):927-938.

PMID: 38775220 PMC: 11483971. DOI: 10.1111/1346-8138.17278.

References
1.
Moulin A, Clement G, Bosman F, Zografos L, Benhattar J . Methylation of CpG island promoters in uveal melanoma. Br J Ophthalmol. 2008; 92(2):281-5. DOI: 10.1136/bjo.2007.127035. View

2.
Carr S, Smith C, Wernberg J . Epidemiology and Risk Factors of Melanoma. Surg Clin North Am. 2019; 100(1):1-12. DOI: 10.1016/j.suc.2019.09.005. View

3.
Palmieri G, Ombra M, Colombino M, Casula M, Sini M, Manca A . Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. Front Oncol. 2015; 5:183. PMC: 4530319. DOI: 10.3389/fonc.2015.00183. View

4.
Druck T, Cheung D, Park D, Trapasso F, Pichiorri F, Gaspari M . Fhit-Fdxr interaction in the mitochondria: modulation of reactive oxygen species generation and apoptosis in cancer cells. Cell Death Dis. 2019; 10(3):147. PMC: 6377664. DOI: 10.1038/s41419-019-1414-7. View

5.
Gaudio E, Paduano F, Spizzo R, Ngankeu A, Zanesi N, Gaspari M . Fhit delocalizes annexin a4 from plasma membrane to cytosol and sensitizes lung cancer cells to paclitaxel. PLoS One. 2013; 8(11):e78610. PMC: 3819369. DOI: 10.1371/journal.pone.0078610. View